Obexelimab met the primary endpoint demonstrating a clinically meaningful and highly statistically significant 56% reduction ...
BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB0) (OTCQB: BVAXF) ("BioVaxys" or the "Company"), a clinical stage biotechnology company focused on developing advanced treatments in oncology, infectious ...
Merck begins phase 3 KANDLELIT-007 trial of calderasib in combo Keytruda QLEX in certain patients with advanced NSCLC: Rahway, New Jersey Friday, January 9, 2026, 15:00 Hrs [IST] ...
The FDA approved Scinopharm's glatiramer acetate injection, a generic version of Copaxone, to treat multiple sclerosis.
Enable Injections closed a $215 million Series C financing in January 2022 led by Magnetar Capital, including Sanofi and multiple additional new institutional investors. Enable received significant ...
Oxford University Hospitals launches UK arm of FORTIFY trial, testing orticumab for coronary inflammation in heart attack patients.
Phase 3 trial data show subcutaneous anifrolumab improves BICLA response rates and reduces oral corticosteroid use in systemic lupus erythematosus.
A new drug application (NDA) has been submitted to the FDA seeking approval of rusfertide, an investigational hepcidin ...
Atacicept, a novel dual inhibitor of BAFF and APRIL, receives FDA Priority Review for IgA nephropathy treatment in adults.
They’ve been hailed as game-changers for weight loss, but new research suggests the results may not last. From how the ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of KANDLELIT-007, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback